Cart
sales@molnova.com
Droxinostat
CAS No. 99873-43-5
Droxinostat ( NS 41080;NS-41080;NS41080 )
Catalog No. M16918 CAS No. 99873-43-5
Droxinostat (NS-41080) is a selective HDAC inhibitor with IC50 of 16.9, 2.47 and 1.46 uM for HDAC3, HDAC6 and HDAC8, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 28 | In Stock |
|
| 5MG | 41 | In Stock |
|
| 10MG | 78 | In Stock |
|
| 25MG | 167 | In Stock |
|
| 50MG | 250 | In Stock |
|
| 100MG | 372 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDroxinostat
-
NoteResearch use only, not for human use.
-
Brief DescriptionDroxinostat (NS-41080) is a selective HDAC inhibitor with IC50 of 16.9, 2.47 and 1.46 uM for HDAC3, HDAC6 and HDAC8, respectively.
-
DescriptionDroxinostat (NS-41080) is a selective HDAC inhibitor with IC50 of 16.9, 2.47 and 1.46 uM for HDAC3, HDAC6 and HDAC8, respectively; does not inhibit HDAC1, HDAC2, HDAC4, HDAC5, HDAC7, HDAC9, and HDAC10 with IC50 of >20 uM; sensitizes malignant cells to death receptor ligands FAS and TRAIL sensitization with IC50 of 20 and 39 uM, respectively; decreases the expression of the caspase-8 inhibitor FLIP, downregulates c-FLIP(L) and c-FLIP(S) mRNA and protein levels, causes PARP degradation, reduces cell survival, and induces apoptosis in MCF-7 breast cancer cells.
-
SynonymsNS 41080;NS-41080;NS41080
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC10;HDAC3;HDAC6;HDAC8;HDAC9
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number99873-43-5
-
Formula Weight243.70
-
Molecular FormulaC11H14ClNO3
-
Purity>98% (HPLC)
-
Solubility10 mM in DMSO
-
SMILESO=C(NO)CCCOC1=CC=C(Cl)C=C1C
-
Chemical NameButanamide, 4-(4-chloro-2-methylphenoxy)-N-hydroxy-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Wood TE, et al. Mol Cancer Ther. 2010 Jan;9(1):246-56.
2. Bijangi-Vishehsaraei K, et al. Mol Cell Biochem. 2010 Sep;342(1-2):133-142.
3. McCourt C, et al. Clin Cancer Res. 2012 Jul 15;18(14):3822-33.
4. Liu J, et al. Transl Oncol. 2016 Feb;9(1):70-78.
2. Bijangi-Vishehsaraei K, et al. Mol Cell Biochem. 2010 Sep;342(1-2):133-142.
3. McCourt C, et al. Clin Cancer Res. 2012 Jul 15;18(14):3822-33.
4. Liu J, et al. Transl Oncol. 2016 Feb;9(1):70-78.
molnova catalog
related products
-
SKLB-23bb
SKLB-23bb is an orally bioavailable HDAC6-selective inhibitor and also has microtubule-disrupting ability.
-
SB-379278A
A potent and selective HDAC8 inhibitor with IC50 of 0.5 uM.
-
GSK-3117391
GSK-3117391 (CHR-5154) is a novel macrophage-targeted HDAC inhibitor.
